EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas

Nicholas P Tschernia, Hillary Heiling, Allison M Deal, Catherine Cheng, Caroline Babinec, Megan Gonzalez, J Kaitlin Morrison, Christopher Dittus, Gianpietro Dotti, Anne W Beaven, Jonathan S Serody, William A Wood und 2 weitere

Journal for ImmunoTherapy of Cancer · 2023

DOI: 10.1136/jitc-2023-006959 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Nicholas P Tschernia und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Service, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Lymphoma, Hematologic Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, Stand Up To Cancer, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)-T cells targeting CD30 have demonstrated high response rates with durable remissions observed in a subset of patients with relapsed/refractory CD30+ hematologic malignancies, particularly classical Hodgkin lymphoma. This therapy has low rates of toxicity including cytokine release syndrome with no neurotoxicity observed in our phase 2 study. We collected patient-reported outcomes (PROs) on patients treated with CD30 directed CAR-T cells to evaluate the impact of this therapy on their symptom experience. We collected PROs including PROMIS (Patient-Reported Outcomes Measurement Information System) Global Health and Physical Function questionnaires and selected symptom questions from the NCI PRO-CTCAE in patients enrolled on our clinical trial of CD30-directed CAR-T cells at procurement, at time of CAR-T cell infusion, and at various time points post treatment. We compared PROMIS scores and overall symptom burden between pre-procurement, time of infusion, and at 4 weeks post infusion. At least one PRO measurement during the study period was found in 23 out of the 28 enrolled patients. Patient overall symptom burden, global health and mental health, and physical function were at or above baseline levels at 4 weeks post CAR-T cell infusion. In addition, PROMIS scores for patients who participated in the clinical trial were similar to the average healthy population. CD30 CAR-T cell therapy has a favorable toxicity profile with patient physical function and symptom burden recovering to at least their baseline pretreatment health by 1 month post infusion. Trial registration number: NCT02690545 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphomaHematologic NeoplasmsHumansReceptors, Antigen, T-CellNeoplasm Recurrence, LocalPatient Reported Outcome MeasuresT-Lymphocytes

Stichwörter der Autor:innen

Hematologic NeoplasmsImmunotherapyReceptors, Chimeric Antigen

Substanzen

Receptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Medical Oncology Service, National Institutes of Health, Bethesda, Maryland, USA.
  • Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Department of Medicine, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
  • Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
  • Department of Pediatrics, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
  • Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA natalie_grover@med.unc.edu.

ORCID-Profile: Natalie S Grover

Förderung

  • NHLBI NIH HHS
  • Stand Up To Cancer
  • National Heart, Lung, and Blood Institute
  • Lineberger Comprehensive Cancer Center
  • Lymphoma Research Foundation

Zitieren

APA

Tschernia, N. P., Heiling, H., Deal, A. M., Cheng, C., Babinec, C., Gonzalez, M., Morrison, J. K., Dittus, C., Dotti, G., Beaven, A. W., Serody, J. S., Wood, W. A., Savoldo, B., & Grover, N. S. (2023). Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-006959

Vancouver

Tschernia NP, Heiling H, Deal AM, Cheng C, Babinec C, Gonzalez M, et al. Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2023-006959

BibTeX
@article{Tschernia2023,
  author = {Tschernia, Nicholas P and Heiling, Hillary and Deal, Allison M and Cheng, Catherine and Babinec, Caroline and Gonzalez, Megan and Morrison, J Kaitlin and Dittus, Christopher and Dotti, Gianpietro and Beaven, Anne W and Serody, Jonathan S and Wood, William A and Savoldo, Barbara and Grover, Natalie S},
  title = {Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  doi = {10.1136/jitc-2023-006959}
}
Kostenlos starten →